SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs & Pharmaceuticals - Quaterly Results

09 Nov 2024 Evaluate
The sales slipped to Rs. 3283.49 millions for the September 2024 quarter as against Rs. 4469.98 millions during the year-ago period.A slender decline of -4.51% was recorded to Rs. 503.66  millions from Rs. 527.47 millions in the corresponding previous quarter.The Operating Profit of the company witnessed a decrease to 751.90 millions from 1114.76 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202409 202309 % Var
Sales 3283.49 4469.98 -26.54 3283.49 4469.98 -26.54 3283.49 4469.98 -26.54
Other Income 321.24 221.68 44.91 321.24 221.68 44.91 321.24 221.68 44.91
PBIDT 751.90 1114.76 -32.55 751.90 1114.76 -32.55 751.90 1114.76 -32.55
Interest 41.83 45.08 -7.21 41.83 45.08 -7.21 41.83 45.08 -7.21
PBDT 710.07 888.68 -20.10 710.07 888.68 -20.10 710.07 888.68 -20.10
Depreciation 93.87 78.97 18.87 93.87 78.97 18.87 93.87 78.97 18.87
PBT 616.20 809.71 -23.90 616.20 809.71 -23.90 616.20 809.71 -23.90
TAX 112.54 282.24 -60.13 112.54 282.24 -60.13 112.54 282.24 -60.13
Deferred Tax -24.58 129.71 -118.95 -24.58 129.71 -118.95 -24.58 129.71 -118.95
PAT 503.66 527.47 -4.51 503.66 527.47 -4.51 503.66 527.47 -4.51
Equity 306.21 286.13 7.02 306.21 286.13 7.02 306.21 286.13 7.02
PBIDTM(%) 22.90 24.94 -8.18 22.90 24.94 -8.18 22.90 24.94 -8.18

Akums Drugs & Pharma Share Price

534.10 0.75 (0.14%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×